BR112015025058A2 - composição farmacêutica capaz de controlar facilmente o padrão de dissolução de lacosamida ou de um sal farmaceuticamente aceitável da mesma - Google Patents

composição farmacêutica capaz de controlar facilmente o padrão de dissolução de lacosamida ou de um sal farmaceuticamente aceitável da mesma

Info

Publication number
BR112015025058A2
BR112015025058A2 BR112015025058A BR112015025058A BR112015025058A2 BR 112015025058 A2 BR112015025058 A2 BR 112015025058A2 BR 112015025058 A BR112015025058 A BR 112015025058A BR 112015025058 A BR112015025058 A BR 112015025058A BR 112015025058 A2 BR112015025058 A2 BR 112015025058A2
Authority
BR
Brazil
Prior art keywords
lacosamide
pharmaceutically acceptable
pharmaceutical composition
acceptable salt
composition capable
Prior art date
Application number
BR112015025058A
Other languages
English (en)
Other versions
BR112015025058B1 (pt
BR112015025058A8 (pt
Inventor
Young Ko Chan
Mo Koo Hyoung
Oh Myeongjun
Joon Lee Sang
Original Assignee
Bio Pharmartis Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Pharmartis Co Ltd filed Critical Bio Pharmartis Co Ltd
Publication of BR112015025058A2 publication Critical patent/BR112015025058A2/pt
Publication of BR112015025058A8 publication Critical patent/BR112015025058A8/pt
Publication of BR112015025058B1 publication Critical patent/BR112015025058B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

resumo patente de invenção: "composição farmacêutica capaz de controlar facilmente o padrão de dissolução de lacosamida ou de um sal farmaceuticamente aceitável da mesma". a presente invenção refere-se a uma composição farmacêutica do tipo matriz contendo lacosamida, que é um princípio ativo, ou um sal farmaceuticamente aceitável da mesma. mais especificamente, a presente invenção refere-se a uma composição farmacêutica capaz de controlar facilmente o padrão de dissolução de uma quantidade eficaz de lacosamida ou um sal farmaceuticamente aceitável da mesma.
BR112015025058-0A 2013-04-02 2014-03-24 Composição farmacêutica do tipo matriz contendo lacosamida BR112015025058B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2013-0035989 2013-04-02
KR1020130035989A KR101732731B1 (ko) 2013-04-02 2013-04-02 라코사마이드(lacosamide) 또는 이의 약학적으로 허용 가능한 염의 용출 패턴 조절이 용이한 약학 조성물
PCT/KR2014/002454 WO2014163314A1 (ko) 2013-04-02 2014-03-24 라코사마이드(lacosamide) 또는 이의 약학적으로 허용 가능한 염의 용출 패턴 조절이 용이한 약학 조성물

Publications (3)

Publication Number Publication Date
BR112015025058A2 true BR112015025058A2 (pt) 2017-07-18
BR112015025058A8 BR112015025058A8 (pt) 2023-01-03
BR112015025058B1 BR112015025058B1 (pt) 2023-11-21

Family

ID=51658558

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015025058-0A BR112015025058B1 (pt) 2013-04-02 2014-03-24 Composição farmacêutica do tipo matriz contendo lacosamida

Country Status (4)

Country Link
KR (1) KR101732731B1 (pt)
CN (1) CN105228608B (pt)
BR (1) BR112015025058B1 (pt)
WO (1) WO2014163314A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104784134B (zh) * 2015-04-12 2018-05-29 石家庄四药有限公司 一种拉科酰胺固体制剂及其制备方法
EP3397253A1 (en) 2015-12-30 2018-11-07 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders
WO2018062955A1 (ko) * 2016-09-29 2018-04-05 에스케이케미칼(주) 라코사미드 서방성 제제
KR102083241B1 (ko) * 2018-02-14 2020-03-02 환인제약 주식회사 라코사미드를 함유하는 약제학적 서방성 조성물
CN109010301B (zh) * 2018-09-05 2021-01-26 上海上药第一生化药业有限公司 一种拉考沙胺晶型ii片剂及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011008298A2 (en) * 2009-07-16 2011-01-20 Nectid, Inc. Novel axomadol dosage forms
MX350056B (es) * 2009-11-03 2017-08-25 Lupin Ltd Formulacion de liberacion modificada de lacosamida.
WO2011101863A2 (en) 2010-02-19 2011-08-25 Cadila Healthcare Limited Extended release pharmaceutical compositions of lacosamide
EP2468261A1 (en) * 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
EP2645997B1 (en) 2010-12-02 2022-08-10 UCB Pharma GmbH Once daily formulation of lacosamide

Also Published As

Publication number Publication date
CN105228608A (zh) 2016-01-06
BR112015025058B1 (pt) 2023-11-21
CN105228608B (zh) 2019-05-28
WO2014163314A1 (ko) 2014-10-09
KR20140120191A (ko) 2014-10-13
KR101732731B1 (ko) 2017-05-08
BR112015025058A8 (pt) 2023-01-03

Similar Documents

Publication Publication Date Title
BR112015018738A8 (pt) compostos de tetra-hidropirrolotiazina, seus usos, e composição farmacêutica
CU20150014A7 (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
BR112015016911A2 (pt) tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn
BR112015012197A2 (pt) terapia de combinação
BR112016011755A2 (pt) derivado de ureia ou sal farmacologicamente aceitável do mesmo
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
BR112015022972A2 (pt) composição farmacêutica de cloridrato de s-cetamina
BR112013022495A2 (pt) formulação farmacêutica aquosa de tapentadol para administração oral
EA201500365A1 (ru) Комбинация регорафениба и ацетилсалициловой кислоты для лечения рака
BR112015016930A2 (pt) formulações farmacêuticas estabilizadas de análogos de insulina e/ou derivados de insulina
BR112015011430A2 (pt) composição para liberação imediata e prolongada
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
BR112013017302A2 (pt) formulações de imunossupressor
BR112015010791A2 (pt) moduladores de gpr40 de di-hidropirazol
BR112015026967A8 (pt) fenoxietil di-hidro-1h-isoquinolina, seus usos, e composição farmacêutica
BR112015025058A2 (pt) composição farmacêutica capaz de controlar facilmente o padrão de dissolução de lacosamida ou de um sal farmaceuticamente aceitável da mesma
BR112016026552A8 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
UY35209A (es) Compuestos tricíclicos
MD3359146T2 (ro) Compoziții farmaceutice și utilizări direcționate spre bolile de depozitare lizozomală
UY35211A (es) Compuestos tricíclicos
BR112017022846A2 (pt) combinação de dose fixa inviolável que proporciona rápida liberação de dois fármacos de partículas diferentes
EA201692298A1 (ru) Производные карбоксамидов
UY33568A (es) Compuestos que interactuan con proteina reguladora de glucocinasa para el tratamiento de diabetes.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: BIOINNOTIS CO., LTD. (KR)

B25A Requested transfer of rights approved

Owner name: HYUNDAI PHARM CO., LTD. (KR)

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/03/2014, OBSERVADAS AS CONDICOES LEGAIS